InMed Pharmaceuticals (INM) Capital Expenditures (2019 - 2024)

InMed Pharmaceuticals (INM) reported Capital Expenditures of $2.0 for Q1 2024, down 99.99% quarter-over-quarter from $31816.0 in Q2 2023.

InMed Pharmaceuticals (INM) Capital Expenditures (2019 - 2024) Analysis & Trends

InMed Pharmaceuticals has reported Capital Expenditures for 6 years, with the latest figure at $2.0 in Q1 2024.

For the quarter ending Q1 2024, Capital Expenditures changed N/A year-over-year to $2.0; the trailing twelve-month figure through Jun 2024 stood at $31818.0 (up 117.77% YoY), and the FY2024 full-year result was $9293.0, down 94.19% from the prior year.
Capital Expenditures for Q1 2024 stood at $2.0, down from $31816.0 in the prior quarter.
The five-year high for Capital Expenditures was $250000.0 in Q3 2021, with the low at -$214445.0 in Q4 2021.
Historically, Capital Expenditures has averaged $11256.9 across 5 years, with a median of $3553.0 in 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Capital Expenditures (Qtr)
1	Teva Pharmaceutical Industries	39.72 Bn	35.98 Bn	1.97 Bn	168.00 Mn
2	Zoetis	34.61 Bn	32.67 Bn	1.62 Bn	110.00 Mn
3	United Therapeutics	24.07 Bn	21.91 Bn	648.10 Mn	100.80 Mn
4	Aurora Cannabis	16.98 Bn	16.91 Bn	33.43 Mn	-
5	Neurocrine Biosciences	16.64 Bn	15.32 Bn	800.70 Mn	9.10 Mn
6	Elanco Animal Health	12.19 Bn	11.76 Bn	785.00 Mn	51.00 Mn
7	Alkermes	7.37 Bn	6.86 Bn	-116.06 Mn	4.09 Mn
8	Hims & Hers Health	6.62 Bn	5.87 Bn	396.79 Mn	8.83 Mn
9	Lantheus Holdings	6.47 Bn	5.97 Bn	230.92 Mn	2.04 Mn
10	InMed Pharmaceuticals	6.04 Mn	796,124.14	-	-

Download Data